Adjunctive Clobazam Efficacy Study for Drug-Resistant Epilepsy

January 2023 to May 2025 data from a single-center study of 121 Chinese patients with drug-resistant epilepsy. The dataset tracks seizure frequency, treatment dosage, adverse events, and response rates over 12-month follow-ups at 1, 3, 6, 9, and 12 months.

Use Cases

• Model seizure freedom probability using age at medication, CLB dosage, and oxcarbazepine co-therapy as predictors.
• Analyze temporal trends in response rates (≥50% seizure reduction) across the five follow-up time points.
• Compare adverse event rates, such as somnolence/mental fatigue and hypersomnia, across different patient demographics or treatment durations.
• Investigate the association between concomitant valproate use and low response rate outcomes.

Strengths

• Contains detailed longitudinal data with follow-up assessments at five specific time points over 12 months.
• Includes 121 patient records with specific metrics like mean age (32.4 ± 13.5 years) and mean number of prior failed medications (3).
• Reports statistical findings, such as p-values and odds ratios, for predictors like CLB dosage and oxcarbazepine co-therapy.

Limitations

• Small sample size of 121 patients limits statistical power for subgroup analyses.
• Single-center study from one Chinese hospital, limiting geographic and institutional generalizability.
• Data is presented in a DOCX document, not a structured tabular format, requiring extraction for computational analysis.

Provenance

Source

Epilepsy Center of the Seventh Affiliated Hospital of Sun Yat-sen University.

Collection Method

Retrospective clinical study.

Time Range

January 2023 to May 2025.

Freshness

Data covers up to May 2025; metadata last updated March 2026.

Geography

China (single-center).